肿瘤患者化疗期间测定尿微量白蛋白、α_1-微球蛋白和免疫球蛋白G的临床意义  

Clinical significance of determine urine mAlb,α_1-MG and IgG in cancer patients during chemotherapy

作　　者：王雷[1] 高莉华[1] 郭秀梅[1] 李尧[1] 焦桂复[1] 

机构地区：[1]吉林市第二中心医院肿瘤科,吉林132001

出　　处：《中国肿瘤临床与康复》2011年第6期500-502,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨测定尿微量白蛋白、α1-微球蛋白和免疫球蛋白G,对肿瘤患者化疗期间肾功监测的临床意义。方法 130例患者在化疗前1天及化疗第10天检测尿微量白蛋白、α1-微球蛋白和免疫球蛋白G,并检测患者同期的血肌酐及尿素。结果化疗前、后患者尿微量白蛋白、α1-微球蛋白和免疫球蛋白G数值变化明显,差异有统计学意义(P<0.01),而化疗前后血尿素和肌酐数值无明显变化,差异无统计学意义(P>0.05)。结论应用尿微量白蛋白、α1-微球蛋白和免疫球蛋白G作为肿瘤化疗患者肾功监测指标,较常规指标血尿素氮、肌酐更灵敏,可早期有效地反映化疗所致患者肾功能损害。Objective To study the urine MA,α1 -MG and IgG in cancer patients during chemother- apy and to evaluate their diagnostic value for early renal damage. Methods Detect urine MA,α1-MG and IgG of 130 cancer patients on the day before chemotherapy （D0 ）and the tenth day of chemotherapy（ D0 ）. Detect blood BUN and Scr at the same time. Results The level of urine MA,α1-MG and IgG on D10 were higher than that of DO （P 〈 0. 01 ）. The level of blood BUN and SCr on D0 and on D10 owere no different. Conclusion Urine MA,α1-MG and IgG can be used as indicators of early renal damage for cancer patients during chemotherapy. They had higher diagnostic value and were more sensitive than blood BUN and SCr.

关 键 词：尿白蛋白 球蛋白类 肿瘤 药物疗法 肾功能不全 

分 类 号：R730.5[医药卫生—肿瘤]